Cargando…
Single‐Dose and Multiple‐Dose Pharmacokinetics of Vaniprevir in Healthy Men
Vaniprevir is an inhibitor of the hepatitis C virus (HCV) NS3/4A protease. The aim of these double‐blind, placebo‐controlled phase I studies was to evaluate the safety and pharmacokinetics of vaniprevir in healthy male volunteers. The primary objective for both studies was the safety and tolerabilit...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402189/ https://www.ncbi.nlm.nih.gov/pubmed/28796416 http://dx.doi.org/10.1111/cts.12482 |
_version_ | 1783400344293736448 |
---|---|
author | Caro, L de Hoon, J Depré, M Cilissen, C Miller, J Gao, W Panebianco, D Guo, Z Troemel, SL Anderson, MS Uemura, N Butterton, J Wagner, J Wright, DH |
author_facet | Caro, L de Hoon, J Depré, M Cilissen, C Miller, J Gao, W Panebianco, D Guo, Z Troemel, SL Anderson, MS Uemura, N Butterton, J Wagner, J Wright, DH |
author_sort | Caro, L |
collection | PubMed |
description | Vaniprevir is an inhibitor of the hepatitis C virus (HCV) NS3/4A protease. The aim of these double‐blind, placebo‐controlled phase I studies was to evaluate the safety and pharmacokinetics of vaniprevir in healthy male volunteers. The primary objective for both studies was the safety and tolerability of vaniprevir. Single‐dose and steady‐state pharmacokinetics were also assessed. In both studies, there was no apparent relationship between the frequency or intensity of adverse events and vaniprevir dose. At single doses >20 mg, the plasma area under the curve (AUC)(0–∞) and maximum concentration (C(max)) increased in a greater‐than‐dose‐proportional manner. The geometric mean ratios (GMRs; fed/fasted) were 1.22 and 0.79 for AUC(0–∞) and C(max), respectively. Following multiple doses, GMR accumulations for AUC(0–12h) and C(max) (day 14/day 1) ranged from 1.53 to 1.90 and from 1.41 to 1.92, respectively. These data support the use of vaniprevir with peginterferon and ribavirin in patients with HCV infection. |
format | Online Article Text |
id | pubmed-6402189 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64021892019-03-18 Single‐Dose and Multiple‐Dose Pharmacokinetics of Vaniprevir in Healthy Men Caro, L de Hoon, J Depré, M Cilissen, C Miller, J Gao, W Panebianco, D Guo, Z Troemel, SL Anderson, MS Uemura, N Butterton, J Wagner, J Wright, DH Clin Transl Sci Research Vaniprevir is an inhibitor of the hepatitis C virus (HCV) NS3/4A protease. The aim of these double‐blind, placebo‐controlled phase I studies was to evaluate the safety and pharmacokinetics of vaniprevir in healthy male volunteers. The primary objective for both studies was the safety and tolerability of vaniprevir. Single‐dose and steady‐state pharmacokinetics were also assessed. In both studies, there was no apparent relationship between the frequency or intensity of adverse events and vaniprevir dose. At single doses >20 mg, the plasma area under the curve (AUC)(0–∞) and maximum concentration (C(max)) increased in a greater‐than‐dose‐proportional manner. The geometric mean ratios (GMRs; fed/fasted) were 1.22 and 0.79 for AUC(0–∞) and C(max), respectively. Following multiple doses, GMR accumulations for AUC(0–12h) and C(max) (day 14/day 1) ranged from 1.53 to 1.90 and from 1.41 to 1.92, respectively. These data support the use of vaniprevir with peginterferon and ribavirin in patients with HCV infection. John Wiley and Sons Inc. 2017-08-10 2017-11 /pmc/articles/PMC6402189/ /pubmed/28796416 http://dx.doi.org/10.1111/cts.12482 Text en © 2017 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Caro, L de Hoon, J Depré, M Cilissen, C Miller, J Gao, W Panebianco, D Guo, Z Troemel, SL Anderson, MS Uemura, N Butterton, J Wagner, J Wright, DH Single‐Dose and Multiple‐Dose Pharmacokinetics of Vaniprevir in Healthy Men |
title | Single‐Dose and Multiple‐Dose Pharmacokinetics of Vaniprevir in Healthy Men |
title_full | Single‐Dose and Multiple‐Dose Pharmacokinetics of Vaniprevir in Healthy Men |
title_fullStr | Single‐Dose and Multiple‐Dose Pharmacokinetics of Vaniprevir in Healthy Men |
title_full_unstemmed | Single‐Dose and Multiple‐Dose Pharmacokinetics of Vaniprevir in Healthy Men |
title_short | Single‐Dose and Multiple‐Dose Pharmacokinetics of Vaniprevir in Healthy Men |
title_sort | single‐dose and multiple‐dose pharmacokinetics of vaniprevir in healthy men |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402189/ https://www.ncbi.nlm.nih.gov/pubmed/28796416 http://dx.doi.org/10.1111/cts.12482 |
work_keys_str_mv | AT carol singledoseandmultipledosepharmacokineticsofvaniprevirinhealthymen AT dehoonj singledoseandmultipledosepharmacokineticsofvaniprevirinhealthymen AT deprem singledoseandmultipledosepharmacokineticsofvaniprevirinhealthymen AT cilissenc singledoseandmultipledosepharmacokineticsofvaniprevirinhealthymen AT millerj singledoseandmultipledosepharmacokineticsofvaniprevirinhealthymen AT gaow singledoseandmultipledosepharmacokineticsofvaniprevirinhealthymen AT panebiancod singledoseandmultipledosepharmacokineticsofvaniprevirinhealthymen AT guoz singledoseandmultipledosepharmacokineticsofvaniprevirinhealthymen AT troemelsl singledoseandmultipledosepharmacokineticsofvaniprevirinhealthymen AT andersonms singledoseandmultipledosepharmacokineticsofvaniprevirinhealthymen AT uemuran singledoseandmultipledosepharmacokineticsofvaniprevirinhealthymen AT buttertonj singledoseandmultipledosepharmacokineticsofvaniprevirinhealthymen AT wagnerj singledoseandmultipledosepharmacokineticsofvaniprevirinhealthymen AT wrightdh singledoseandmultipledosepharmacokineticsofvaniprevirinhealthymen |